Objective To study the clinicopathological characteristies,differential diagnosis,etiological factor and treatment of anorectal malignant melanoma(AMM). Methods Clinical pathological characteristics and immunohistochemical findings were observed in 13 cases of anorectal malignant melanoma,with review of related literature.Results Average age was 55.8 years. And often occurred in the middle and old. Under microscope, the tumor was complicated constructionally, and the tumor cells were variform. Usually in tightly packed nests, dispersed sheet and trabecular, melanin pigment could be observed in the majority of AMM, but sometimes ameLanotic pigment was present. Immunohistochemiscal the tumor cells were positive for HMB 45, S-100 and vimetin. Conclnsion AMM is a high malignant tumor with very poor prognosis. So,it should be diagnosed and treated early. HMB 45 and S-100 are sensitive tumor markers for AMM.

Objective To investigate the synergetic effect of Aiyishu injection in combination with neoadjuvant chemotherapy in the treatment patients with breast cancer.Methods Seventy patients with breast carcinoma at stage Ⅰ - Ⅲ were randomly divided into treatment group( Aiyishu associated CAF regimen)( n =36) and control group ( CAF regimen) ( n =34).The activities of T cells and NK cells,response rate,change of clinical symptoms,adverse effects and living quality were evaluated in patients of two groups.Results The levels of CD3,CD4,CD8 and the ratio of CD4/CD8 and the activity of NK cells in treatment group were higher than those in control group( P ＜0.05) ;the response rate was 41.67％ and 36.67％ in group 1 and 2 respectively,but had no significant difference;the incidence rates of leucopenia and gastrointestinal disturbance were 33.33％ and 38.89％ respectively in patients of treatment group,whereas the rates were 67.65％ and 67.65 ％,in control group ( P ＜ 0.05).In treatment group,KPS increased in 36.11％ (13/36) patients,and it was higher than that in control group (11.76％,4/34 )( P ＜0.05).Conclusion Aiyishu injection can increase the ability of immunity of body and reduce the toxic and adverse reaction,and improve the living quality in patients with breast cancer when it is used in pre-operative chemotherapy of breast cancer.

Objective To investigate new type cytokine induced killer cells expansion using advanced breast cancer′s peripheral blood .Methods peripheral blood mononuclear cells were isolated from 8 advanced breast cancer volunteers and co -cultured with Cytokine induced killer cells .These cells were placed in plastic flasks containing CIK-MediumTM supplemented with 10% auto-plasma in the presence of IL -2 ( 1 000 IU/mL) .The cultures were fed with CIK-MediumTM supplemented with IL -2 following the proliferation capacity . Cell proliferation was measured by cell counting during the cultivation .Fourteen days after cultivation ,cell mark-ers CD3/CD16/CD56 were examined by flow cytometry .51Cr and MTT assays were employed in cytotoxicity as-says.Cytokines were assayed by ELISA method .Results CD16+,CD16+CD56+,CD56+CIK cells were 5.8~11.6%in 2 ×107 fresh PBMCs and 95.2~97.6%in co-cultured cells after 18 days cultivation .The in vitro ex-pansion rate of new type cytokine induced killer cells was up to more than 8.2 ×108 in total,the cytotoxicity are ef-fective killing cells against MCF 7 and BT20 breast cancer cell lines .New type cytokine induced killer cells expand-ed from all PBMCs and secreted cytokines IFN -and TNF-.Conclusion The present culture could be useful to clarify the mechanisms of CIK cells expansion in vitro and feasible for breast cancer immmuno cell therapy .